TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
09 Décembre 2021 - 12:50PM
Business Wire
-- Oral SM-88 is an investigational cancer
metabolism-based therapy that has demonstrated clinical responses
across 15 different types of solid tumors and hematologic cancers
–
-- Prestigious conference features new,
innovative findings in gastrointestinal cancer treatment, research
and care –
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an
emerging biotechnology company developing cancer metabolism-based
therapies (CMBTs™), today announced that its abstract, Oral SM-88
plus MPS, an effective yet less toxic treatment option in
second-line advanced pancreatic cancer? Final phase II/III study
results, has been accepted for poster presentation at the 2022
American Society of Clinical Oncology (ASCO) Gastrointestinal
Cancers Symposium, January 20 – 22, 2022, in San Francisco, CA.
“We are delighted that our abstract was chosen from among the
more than 750 submissions that were reviewed by the Symposium
Program Committee, and we look forward to sharing more information
about this important work at the conference,” stated Richie
Cunningham, Chief Executive Officer of TYME.
Additional information on the meeting can be found on the ASCO
2022 Gastrointestinal Cancers Symposium website
https://conferences.asco.org/gi/program.
Poster Presentation
Details:
Abstract Number: 585
Abstract Title: Oral SM-88 plus MPS, an effective yet
less toxic treatment option in second-line advanced pancreatic
cancer? Final phase II/III study results.
Session Information: Poster Session B: Pancreas, Small
Bowel, and Hepatobiliary Tract
Date/Time: Friday, January 21, 2022, 3:05 – 4:35 PM
EST
About TYME Technologies, Inc. TYME is an emerging
biotechnology company developing cancer metabolism-based therapies
(CMBTs™) that are intended to be effective across a broad range of
solid tumors and hematologic cancers, while also maintaining
patients’ quality of life through relatively low toxicity profiles.
Unlike targeted therapies that attempt to regulate specific
mutations within cancer, the Company’s therapeutic approach is
designed to take advantage of a cancer cell’s innate metabolic
weaknesses to cause cancer cell death.
The Company is currently focused on developing its novel
compound, SM-88. The Company believes that early clinical results
demonstrated by SM-88 in multiple advanced cancers, including
pancreatic, prostate, sarcomas and breast, reinforce the potential
of its emerging CMBT™ pipeline.
For more information about the Company, visit www.tymeinc.com
and connect on Facebook, LinkedIn, and Twitter.
About SM-88 SM-88 is an oral investigational modified
proprietary tyrosine derivative that is believed to interrupt the
metabolic processes of cancer cells by breaking down the cells’ key
defenses and leading to cell death through oxidative stress and
exposure to the body’s natural immune system. Clinical trial data
have shown that SM-88 has demonstrated encouraging tumor responses
across 15 different cancers, including pancreatic, lung, breast,
prostate and sarcoma cancers with minimal serious grade 3 or higher
adverse events. SM-88 is being evaluated in an adaptive randomized
Phase 2/3 clinical trial for patients with second-line pancreatic
cancer. The Company has begun enrollment in a Phase II study
evaluating SM-88 in breast cancer (HR+/HER2-) in the third quarter
of calendar year 2021, as well as continuing enrollment of a Phase
II study in high-risk metastatic sarcomas. SM-88 is an
investigational therapy that is not approved for any indication in
any disease.
Learn more.
Forward-Looking Statements In addition to historical
information, this press release contains forward-looking statements
under the Private Securities Litigation Reform Act that involve
substantial risks and uncertainties. Such forward-looking
statements within this press release include, without limitation,
statements regarding our drug candidates (including SM-88 and TYME-
18) and their clinical potential and non-toxic safety profiles, our
drug development plans and strategies, ongoing and planned
preclinical or clinical trials, , preliminary data results and the
therapeutic design and mechanisms of our drug candidates. The words
“believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,”
“estimates,” “could,” “should,” “would,” “continue,” “seeks,”
“anticipates,” and similar expressions (including their use in the
negative) are intended to identify forward-looking statements.
Forward-looking statements can also be identified by discussions of
future matters such as: the effect of the COVID-19 pandemic and the
associated impact on the national and global economy as well as
impacts on the Company's ongoing clinical trials and ability to
analyze data from those trials; the cost of development and
potential commercialization of our lead drug candidate and of other
new product candidates; expected releases of interim or final data
from our clinical trials; possible collaborations; the timing,
scope, status, objectives of our ongoing and planned trials; the
success of management transitions and strategic initiatives; and
other statements that are not historical. The forward-looking
statements contained in this press release are based on
management’s current expectations and projections which are subject
to uncertainty, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
These statements involve known and unknown risks, uncertainties and
other factors which may cause the Company’s actual results,
performance or achievements to be materially different from any
historical results and future results, performance or achievements
expressed or implied by the forward-looking statements. These risks
and uncertainties include but are not limited to: the severity,
duration, and economic impact of the COVID-19 pandemic; our ability
to achieve the intended benefits of our strategic initiatives; that
certain information is of a preliminary nature and may be subject
to change; uncertainties inherent in the cost and outcomes of
research and development, including the cost and availability of
acceptable-quality clinical supply, and in the ability to achieve
adequate start and completion dates, as well as uncertainties in
clinical trial design and patient enrollment, dropout or
discontinuation rates; the possibility of unfavorable study
results, including unfavorable new clinical data and additional
analyses of existing data; risks associated with early, initial
data, including the risk that the final data from any clinical
trials may differ from prior or preliminary study data or analyses
and may not support further clinical development; and that past
reported data are not necessarily predictive of future patient or
clinical data outcomes; whether and when any applications or other
submissions for SM-88 or other drug candidates may be filed with
regulatory authorities; whether and when regulatory authorities may
approve any applications or submissions; decisions by regulatory
authorities regarding labeling and other matters that could affect
commercial availability of SM-88 or other drug candidates; the
ability of TYME and its collaborators to develop and realize
collaborative synergies; competitive developments; and the factors
described in the section captioned “Risk Factors” of TYME’s Annual
Report on Form 10-K for the fiscal year ended March 31, 2021 filed
with the U.S. Securities and Exchange Commission on June 10, 2021
as well as subsequent reports we file from time to time with the
U.S. Securities and Exchange Commission available at
www.sec.gov.
The information contained in this press release is as of its
release date and TYME assumes no obligation to update
forward-looking statements contained in this release as a result of
future events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211209005216/en/
Investor Relations: Lisa M. Wilson, In-Site
Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com
Tyme Technologies (NASDAQ:TYME)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tyme Technologies (NASDAQ:TYME)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024